Sweden has adopted its first national strategy for rare health conditions, aiming to improve coordination, equity and access to care between 2026 and 2030.

Sweden adopts first national strategy for rare health conditions

Sveriges riksdag (house of parlament).

The Swedish Government has adopted its first National Strategy for Rare Health Conditions for 2026–2030, marking a significant step towards more coordinated and equitable care for people living with rare conditions. The strategy, “Coordinated support and equitable care”, is available on the Swedish Government website, alongside the official press release.

The strategy responds to the complex and often lifelong needs of people with rare conditions, a group estimated at around half a million individuals in Sweden. It aims to address existing gaps in knowledge, coordination and access to specialised care, which can vary across regions.

Key objectives include improving early and accurate diagnosis, strengthening continuity of care, and ensuring more equal access to healthcare services across the country. The strategy also places strong emphasis on increasing knowledge among healthcare professionals and reinforcing patient involvement in care processes.

In addition, the framework promotes better use of health data and stronger collaboration between national authorities, regional healthcare providers, academia and patient organisations. It also includes measures to further develop newborn screening and other national support structures.

The National Board of Health and Welfare has been tasked with coordinating, supporting and monitoring the implementation of the strategy, alongside targeted funding to reinforce specialised care and national initiatives in the field of rare conditions.

 

Photo by Arild Vågen CC BY-SA 4.0

News & Updates

You might also be interested in

June 7 - June 10
The Open Academy x ERDERA accompanies patient advocates by offering rare-disease specific comprehensive training programmes that empower advocates with the knowledge, skills and confidence they need to engage with different stakeholders as equal partners.
ERDERA’s ethics and regulatory experts are launching a dedicated webinar series to help the rare disease research community navigate two fast-moving areas of biomedical research: Advanced Therapy Medicinal Products (ATMPs) and Artificial Intelligence.
July 24 @ 3:00 pm - 4:00 pm
This webinar will present a theoretical framework for situating ethics across research activities. The framework will then be brought to life through a relevant case study discussion, giving participants a concrete reference point for the episodes ahead.
ERDERA (the European Rare Diseases Research Alliance) has opened its Clinical Trial Call to support multinational early-phase clinical trials in rare diseases. The call will fund studies designed to generate robust clinical evidence, strengthen regulatory readiness and make rare disease trials more feasible across countries.